

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

CLAIMS

We claim:

1. An isolated nucleic acid having a nucleotide sequence selected from the group consisting of:
 - (a) at least 10 consecutive nucleotides of SEQ ID NO: 1;
 - (b) at least 12 consecutive nucleotides of SEQ ID NO: 1;
 - (c) at least 14 consecutive nucleotides of SEQ ID NO: 1;
 - (d) at least 16 consecutive nucleotides of SEQ ID NO: 1;
 - (e) at least 18 consecutive nucleotides of SEQ ID NO: 1; and
 - (f) a sequence complementary to any one of the sequences of (a) –(e).
2. An isolated nucleic acid having a nucleotide sequence selected from the group consisting of:
 - (a) at least 10 consecutive nucleotides of SEQ ID NO: 3;
 - (b) at least 12 consecutive nucleotides of SEQ ID NO: 3;
 - (c) at least 14 consecutive nucleotides of SEQ ID NO: 3;
 - (d) at least 16 consecutive nucleotides of SEQ ID NO: 3;
 - (e) at least 18 consecutive nucleotides of SEQ ID NO: 3; and
 - (f) a sequence complementary to any one of the sequences of (a) –(e).
3. An isolated nucleic acid having a nucleotide sequence selected from the group consisting of:
 - (a) at least 10 consecutive nucleotides of SEQ ID NO: 5;
 - (b) at least 12 consecutive nucleotides of SEQ ID NO: 5;
 - (c) at least 14 consecutive nucleotides of SEQ ID NO: 5;
 - (d) at least 16 consecutive nucleotides of SEQ ID NO: 5;
 - (e) at least 18 consecutive nucleotides of SEQ ID NO: 5; and
 - (f) a sequence complementary to any one of the sequences of (a) –(e).
4. An isolated nucleic acid having a nucleotide sequence selected from the group consisting of:
 - (a) a sequence encoding a CatSper2 protein;

- (b) a sequence encoding at least a transmembrane domain of a CatSper2 protein;
- (c) a sequence encoding at least an extracellular loop of a CatSper2 protein;
- (d) a sequence encoding at least a pore region of a CatSper2 protein;
- (e) a sequence encoding at least an epitope of a CatSper2 protein having high predicted antigenicity; and
- (f) a sequence complementary to any one of the sequences of (a)–(e).

5. An isolated nucleic acid as in claim 43 selected from the group consisting of:

- (a) a sequence encoding SEQ ID NO: 2;
- (b) a sequence encoding SEQ ID NO: 4;
- (c) a sequence encoding SEQ ID NO: 6;
- (d) a sequence encoding a polypeptide comprising residues 104-126, 146-166, 176-195, 206-228, 241-262, and 316-340 of SEQ ID NO: 2;
- (e) a sequence encoding a polypeptide comprising residues 104-126, 146-166, 176-195, 206-228, 241-262, and 316-340 of SEQ ID NO: 4;
- (f) a sequence encoding a polypeptide comprising residues 102-124, 144-164, 174-193, 204-227, 239-260, and 314-338 of SEQ ID NO: 6;
- (g) a sequence encoding a polypeptide comprising residues 127-145, 196-205, and 263-315 of SEQ ID NO: 2;
- (h) a sequence encoding a polypeptide comprising residues 127-145, 196-205, and 265-315 of SEQ ID NO 4;
- (i) a sequence encoding a polypeptide comprising residues 125-143, 194-203, and 261-313 of SEQ ID NO 6;
- (j) a sequence encoding a polypeptide comprising residues 280-303 of SEQ ID NO: 2;
- (k) a sequence encoding a polypeptide comprising residues 280-303 of SEQ ID NO: 4;
- (l) a sequence encoding a polypeptide comprising residues 278-301 of SEQ ID NO: 6;
- (m) a sequence encoding a polypeptide comprising residues 266-275, 386-400, 447-458, and 482-494 of SEQ ID NO: 2;
- (n) a sequence encoding a polypeptide comprising residues 66-99, 266-275, and 394-414 of SEQ ID NO: 4;

(o) a sequence encoding a polypeptide comprising residues 64-89, 262-275 and 562-588 of SEQ ID NO: 6; and

(p) a sequence complementary to any one of the sequences of (a)-(o).

6. An isolated nucleic acid encoding a polypeptide having at least 80% amino acid sequence identity with a polypeptide selected from the group consisting of:
 - (a) a CatSper2 protein;
 - (b) at least a transmembrane domain of a CatSper2 protein;
 - (c) at least an extracellular loop of a CatSper2 protein; and
 - (d) at least a pore region of a CatSper2 protein.
7. An isolated nucleic acid encoding a polypeptide having at least 80% amino acid sequence identity with a CatSper2 protein and having CatSper2 activity in a cell capable of expressing CatSper2 activity.
8. An isolated nucleic acid comprising a nucleotide sequence that hybridizes to at least a portion of a nucleic acid of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 under conditions including a wash step of 1.0 x SSC at 65°C.
9. An isolated nucleic acid as in claim 8 wherein said nucleic acid encodes a polypeptide having CatSper2 activity.
10. A nucleic acid comprising:
 - (i) a nucleotide sequence encoding a polypeptide having CatSper2 activity, wherein said nucleic acid hybridizes to at least a portion of a nucleic acid of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5 under conditions including a wash step of 1.0 x SSC at 65°C; and
 - (ii) a heterologous regulatory region operably joined to said sequence such that said sequence is expressed.
11. A nucleic acid comprising:
 - (i) a nucleotide sequence encoding a polypeptide having at least 80% amino acid sequence identity with an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 6; and

(ii) a heterologous regulatory region operably joined to said sequence such that said sequence is expressed.

12. A kit for detecting at least a portion of a CatSper2 nucleic acid comprising an isolated nucleic acid of any one of claims 1-7 and a means for detecting said isolated nucleic acid.

13. A kit as in claim 12 wherein said means for detecting said isolated nucleic acid comprises a detectable label bound thereto.

14. A kit as in claim 12 wherein said means for detecting said isolated nucleic acid comprises a labeled secondary nucleic acid which specifically hybridizes to said isolated nucleic acid.

15. A vector comprising an isolated nucleic acid of any one of claims 1-11.

16. A vector comprising a genetic construct which expresses a nucleic acid of any one of claims 4-11.

17. A vector as in claim 16 wherein said nucleic acid is operably joined to an exogenous regulatory region.

18. A vector as in claim 16 wherein said nucleic acid is operably joined to heterologous coding sequences to form a fusion vector.

19. A vector comprising an isolated nucleic acid of any one of claims 4-11.

20. A vector comprising an isolated nucleic acid of any one of claims 4-11 operably joined to a reporter gene.

21. A cell transformed with a nucleic acid of any one of claims 4-11.

22. A cell transformed with a genetic construct capable of expressing a nucleic acid of any one of claims 4-11.

23. A cell as in claim 22 wherein said nucleic is operably joined to heterologous coding sequences to encode a fusion protein.
24. A cell as in claim 22 wherein said cell is selected from the group consisting of bacterial cells, yeast cells, insect cells, nematode cells, amphibian cells, rodent cells, and human cells.
25. A cell as in claim 22 wherein said cell is selected from the group consisting of mammalian somatic cells, fetal cells, embryonic stem cells, zygotes, gametes, germ line cells and transgenic animal cells.
26. A non-human transgenic animal, wherein a genetic construct has introduced a modification into a genome of said animal, or an ancestor thereof, and wherein said modification is selected from the group consisting of insertion of a nucleic acid encoding at least a fragment of a CatSper2 protein, inactivation of an endogenous CatSper2 gene, and insertion by homologous recombination of a reporter gene operably joined to CatSper2 regulatory elements.
27. An animal as in claim 26 wherein said modification is insertion of a nucleic acid encoding a polypeptide selected from the group consisting of a CatSper2 protein, at least a transmembrane domain of a CatSper2 protein, at least an extracellular loop of a CatSper2 protein, at least a pore region of a CatSper2 protein, and at least an epitope of a CatSper2 protein having high predicted antigenicity.
28. An animal as in claim 26 wherein said animal is selected from the group consisting of rats, mice, hamsters, guinea pigs, rabbit, dogs, cats, goats, sheep, pigs, and non-human primates.
29. A substantially pure protein preparation comprising a polypeptide selected from the group consisting of:
- (a) a CatSper2 protein;
 - (b) at least a transmembrane domain of a CatSper2 protein;
 - (c) at least an extracellular loop of a CatSper2 protein;

- (d) at least a pore region of a CatSper2 protein; and
- (e) at least an epitope of a CatSper2 protein having high predicted antigenicity.

30. A substantially pure protein preparation as in claim 29 wherein said polypeptide is selected from the group consisting of:

- (a) SEQ ID NO: 2;
- (b) SEQ ID NO: 4;
- (c) SEQ ID NO: 6;
- (d) residues 104-126, 146-166, 176-195, 206-228, 241-262, and 316-340 of SEQ ID NO: 2;
- (e) residues 104-126, 146-166, 176-195, 206-228, 241-262, and 316-340 of SEQ ID NO: 4;
- (f) residues 102-124, 144-164, 174-193, 204-227, 239-260, and 314-338 of SEQ ID NO: 6;
- (g) residues 127-145, 196-205, and 263-315 of SEQ ID NO: 2;
- (h) residues 127-145, 196-205, and 265-315 of SEQ ID NO 4;
- (i) residues 125-143, 194-203, and 261-313 of SEQ ID NO 6;
- (j) residues 280-303 of SEQ ID NO: 2;
- (k) residues 280-303 of SEQ ID NO: 4;
- (l) residues 278-301 of SEQ ID NO: 6;
- (m) residues 266-275, 386-400, 447-458, and 482-494 of SEQ ID NO: 2;
- (n) residues 66-99, 266-275, and 394-414 of SEQ ID NO: 4; and
- (o) residues 64-89, 262-275 and 562-588 of SEQ ID NO: 6.

31. A substantially pure protein preparation comprising a polypeptide having at least 80% amino acid sequence identity with a polypeptide selected from the group consisting of:

- (a) a CatSper2 protein;
- (b) at least a transmembrane domain of a CatSper2 protein;
- (c) at least an extracellular loop of a CatSper2 protein; and
- (d) at least a pore region of a CatSper2 protein.

32. A substantially pure protein preparation comprising a polypeptide having at least 80% amino acid sequence identity with a CatSper2 protein and having CatSper2 activity in a cell capable of expressing CatSper2 activity.
33. A substantially pure antibody preparation comprising an antibody raised against a CatSper2 epitope.
34. A substantially pure antibody preparation as in claim 33 wherein said epitope has high predicted antigenicity.
35. A substantially pure antibody preparation as in claim 33 wherein said epitope comprises an amino acid sequence within the an amino acid sequence selected from the group consisting of residues 266-275, 386-400, 447-458, and 482-494 of SEQ ID NO: 2, residues 66-99, 266-275, and 394-414 of SEQ ID NO: 4, and residues 64-89, 262-275 and 562-588 of SEQ ID NO: 6.
36. A substantially pure antibody preparation as in any one of claims 33-35 wherein said antibody is a monoclonal antibody.
37. A substantially pure antibody preparation as in any one of claims 33-35 wherein said antibody is an antibody fragment selected from the group consisting of an Fab fragment, an F(ab')₂ fragment, an Fv fragment, and a single-chain Fv fragment (scFv).
38. A kit for detecting at least an epitope of a CatSper2 protein comprising an anti-CatSper2 antibody of any one of claims 33-37 and a means for detecting said antibody.
39. A kit as in claim 38 wherein said means for detecting said anti-CatSper2 antibody comprises a detectable label bound thereto.
40. A kit as in claim 38 wherein said means for detecting said anti-CatSper2 antibody comprises a labeled secondary antibody which specifically binds to said anti-CatSper2 antibody.

41. A method of identifying a potential modulator of CatSper2 activity comprising:
- contacting a candidate compound with a cell expressing a CatSper2 protein;
 - measuring an indicator of CatSper2 activity in said cell;
 - determining whether said candidate compound caused an increase or decrease in said indicator relative to a reference level; and
 - identifying said candidate compound as a potential modulator of CatSper2 activity if said compound causes an increase or decrease in said indicator.
42. A method as in claim 41 wherein said indicator is an indicator of the level of mRNA encoding said CatSper2 protein.
43. A method as in claim 41 wherein said indicator is an indicator of the level of CatSper2 protein.
44. A method as in claim 41 wherein said indicator is an indicator of cation flux across a membrane of said cell.
45. A method as in claim 41 wherein said indicator is an indicator of whole cell or channel currents of said cell.
46. A method as in any one of claims 41-45 wherein said cell has been transformed with a genetic construct which expresses a CatSper2 protein.
47. A method as in claim 41 wherein said cell is a mature sperm cell and said indicator is a measure of sperm motility.
48. A method of identifying a potential modulator of CatSper2 activity comprising:
- contacting under physiological conditions a candidate compound with a CatSper2 moiety comprising at least a structural domain of a CatSper2 protein;
 - measuring binding, if any, between said candidate compound and said CatSper2 moiety; and

identifying said candidate compound as a potential modulator of CatSper2 activity if said candidate compound binds to said CatSper2 moiety.

49. A method as in claim 48 wherein said CatSper2 moiety is a polypeptide selected from the group consisting of:
- (a) a CatSper2 protein;
 - (b) at least a transmembrane domain of a CatSper2 protein;
 - (c) at least an extracellular loop of a CatSper2 protein; and
 - (d) at least a pore region of a CatSper2 protein.
50. A method of decreasing the fertility of a male subject comprising: administering to said male a compound which decreases CatSper2 activity.
51. A method of causing reversible infertility in a male subject comprising: administering to said male a compound which decreases CatSper2 activity.
52. A method of contraception comprising: administering to a male subject a compound which decreases CatSper2 activity.
53. A method of contraception comprising: administering to a female subject a compound which decreases CatSper2 activity.
54. A method as in any one of claims 50-53 wherein said compound is in a formulation selected from the group consisting of an injection, a transdermal patch, a bioerodable implant, a lubricant, a moisturizer, a foam, a jelly, and a sponge.
55. A method of contraception as in claim 53 wherein: said female subject is a mammal and said compound is administered into at least one of the vagina, uterus and fallopian tubes of said female.

56. A method as in any one of claims 50-53 wherein said compound is selected from the group consisting of a nucleic acid which is antisense to at least a portion of a CatSper2 gene and an antibody to a CatSper2 protein.

57. A method as in claim 56 wherein said compound is an antibody fragment selected from the group consisting of an Fab fragment, an F(ab')₂ fragment, an Fv fragment, and an scFv fragment.

58. A method as in any one of claims 50-53 wherein said subject is a mammal.

59. A method as in claim 58 wherein said mammal is selected from the group consisting of humans, dogs, cats, cows, sheep, horses, mice, rats, raccoons, and gophers.

60. A method as in claim 58 wherein said subject is selected from the group consisting of a fish, an amphibian and an insect.

61. Use of a compound which decreases CatSper2 activity in the preparation of a medicament for decreasing the fertility of a male subject.

62. Use of a compound which decreases CatSper2 activity in the preparation of a medicament for causing reversible infertility in a male subject.

63. Use of a compound which decreases CatSper2 activity in the preparation of a contraceptive for administration to a male.

64. Use of a compound which decreases CatSper2 activity in the preparation of a contraceptive for administration to a female.

65. A use as in any one of claims 61-64 wherein said compound is in a formulation selected from the group consisting of an injection, a transdermal patch, a bioerodable implant, a lubricant, a moisturizer, a foam, a jelly, and a sponge.

66. A use as in claim 64 wherein:

said female subject is a mammal and said compound is administered into at least one of the vagina, uterus and fallopian tubes of said female.

67. A use as in any one of claims 61-64 wherein said compound is selected from the group consisting of a nucleic acid which is antisense to at least a portion of a CatSper2 gene and an antibody to a CatSper2 protein.
68. A use as in claim 67 wherein said compound is an antibody fragment selected from the group consisting of an Fab fragment, an F(ab')₂ fragment, an Fv fragment, and an scFv fragment.
69. A use as in any one of claims 61-64 wherein said subject is a mammal.
70. A use as in claim 69 wherein said mammal is selected from the group consisting of humans, dogs, cats, cows, sheep, horses, mice, rats, raccoons, and gophers.
71. A use as in claim 69 wherein said subject is selected from the group consisting of a fish, an amphibian and an insect.
72. A contraceptive preparation comprising a compound which decreases CatSper2 activity.
73. A preparation as in claims 72 wherein said compound is selected from the group consisting of a nucleic acid which is antisense to at least a portion of a CatSper2 gene and an antibody to a CatSper2 protein.
74. A preparation as in claim 72 wherein said preparation is in a formulation selected from the group consisting of an injection, a transdermal patch, a bioerodable implant, a lubricant, a moisturizer, a foam, a jelly, and a sponge.
75. A method of diagnosing a CatSper2-related disorder in a mammal comprising determining the presence or absence of a mutation in a CatSper2 gene.

76. A method as in claim 75 wherein said method comprises:
determining at least a portion of a CatSper2 gene sequence and comparing said determined sequence to a reference sequence;
wherein the presence or absence of differences between said determined sequence and said reference sequence indicate the presence or absence of mutations in said CatSper2 gene.
77. A method of diagnosing a CatSper2-related disorder comprising determining the presence or absence of a mutation in a CatSper2 protein.
78. A method as in claim 77 wherein said method comprises:
determining at least a portion of a CatSper2 protein sequence and comparing said determined sequence to a reference sequence;
wherein the presence or absence of differences between said determined sequence and said reference sequence indicate the presence or absence of mutations in said CatSper2 gene.
79. A method as in claim 78 wherein said determination comprises contacting at least a fragment of said CatSper2 protein with an antibody known to bind to a CatSper2 protein in which a mutation is known to be present or absent and detecting binding between said antibody and said fragment of said CatSper2 protein.
80. A method of diagnosing a CatSper2-related disorder in a mammal comprising measuring an indicator of CatSper2 activity in said cell;
comparing said measured indicator to a reference level; and
diagnosing a CatSper2-related disorder if said indicator increases or decreases.
81. A method as in claim 80 wherein said indicator is an indicator of the level of mRNA encoding said CatSper2 protein.
82. A method as in claim 80 wherein said indicator is an indicator of the level of CatSper2 protein.

83. A method as in claim 80 wherein said indicator is an indicator of cation flux across a membrane of said cell.
84. A method as in claim 80 wherein said indicator is an indicator of whole cell or channel currents of said cell.
85. A method as in any one of claims 75-84 wherein said disorder is CatSper2-related infertility.
86. A method of genotyping a subject with respect to a CatSper2 gene comprising:
determining at least a portion of a CatSper2 gene sequence and comparing said determined sequence to a reference sequence;
wherein the presence or absence of differences between said determined sequence and said reference sequence indicate the presence or absence of a genotype corresponding to said reference sequence.
87. A method of genotyping a subject with respect to a CatSper2 gene comprising:
determining at least a portion of a CatSper2 protein sequence and comparing said determined sequence to a reference sequence;
wherein the presence or absence of differences between said determined sequence and said reference sequence indicate the presence or absence of a genotype corresponding to said reference sequence.
88. A method as in claim 87 wherein said determination comprises contacting at least a fragment of said CatSper2 protein with an antibody known to bind to a CatSper2 protein comprising said reference sequence and detecting binding between said antibody and said fragment of said CatSper2 protein.
89. A method of *in vitro* fertilization by sperm having decreased CatSper2 activity comprising:
removing a zona pellucida from at least one ovum;
contacting said ovum with at least one of said sperm; and
allowing said sperm to fertilize said ovum.

90. A method of *in vitro* fertilization by sperm having decreased motility comprising:
- removing a zona pellucida from at least one ovum;
 - contacting said ovum with at least one of said sperm; and
 - allowing said sperm to fertilize said ovum.
91. A method of *in vitro* fertilization by sperm having decreased ability to penetrate a zona pellucida comprising:
- removing a zona pellucida from at least one ovum;
 - contacting said ovum with at least one of said sperm; and
 - allowing said sperm to fertilize said ovum.
92. A method of treating a subject characterized by infertility due to decreased CatSper2 activity comprising:
- transforming sperm or sperm progenitors of said subject with a genetic construct capable of expressing a CatSper2 protein; and
 - using transformed sperm of said subject to fertilize an ovum.
93. A method of treating a subject characterized by infertility due to decreased CatSper2 activity comprising:
- administering a CatSper2 protein to sperm or sperm progenitors of said subject, whereby said protein provides CatSper2 activity in said sperm or spermatids; and
 - using sperm bearing said administered CatSper2 protein to fertilize an ovum.
94. A method of diagnosing an anti-CatSper2 antibody-mediated infertility caused by anti-CatSper2 antibodies present in a female urogenital tract comprising:
- obtaining a sample of antibodies present in a female urogenital tract;
 - contacting said sample of antibodies with at least a fragment of a CatSper2 protein;
 - detecting binding between said sample of antibodies and said fragment of a CatSper2 protein; and
 - diagnosing an anti-CatSper2 antibody-mediated infertility if binding is detected between said sample of antibodies and said fragment of a CatSper2 protein.

95. A method as in claim 94 wherein said CatSper2 fragment comprises a CatSper2 epitopes having high predicted antigenicity.
96. A method as in claim 95 wherein said epitope is included within a sequence selected from the group consisting of residues 266-275, 386-400, 447-458, and 482-494 of SEQ ID NO: 2; residues 66-99, 266-275, and 394-414 of SEQ ID NO: 4; and residues 64-89, 262-275 and 562-588 of SEQ ID NO: 6.
97. A method of treating an anti-CatSper2 antibody-mediated infertility caused by anti-CatSper2 antibodies present in a female urogenital tract, comprising:
administering into said urogenital tract an agent which specifically binds to said anti-CatSper2 antibodies in an amount effective to inhibit binding between said anti-CatSper2 antibodies and a CatSper2 protein present on sperm in said urogenital tract.
98. A method as in claim 97 wherein said agent comprises at least fragment of a CatSper2 protein including an epitope having high predicted antigenicity.
99. A method as in claim 98 wherein said epitope is included within a sequence selected from the group consisting of residues 266-275, 386-400, 447-458, and 482-494 of SEQ ID NO: 2; residues 66-99, 266-275, and 394-414 of SEQ ID NO: 4; and residues 64-89, 262-275 and 562-588 of SEQ ID NO: 6.
100. A method as in claim 98 wherein said agent comprises an anti-idiotypic antibody against said anti-CatSper2 antibodies.
101. A method of conducting a drug discovery business comprising:
- (a) identifying, by the assay of claim 41, one or more agents which antagonize CatSper2 activity;
 - (b) determining if an agent identified in step (a), or an analog thereof, inhibits at least one of sperm motility or egg penetrance;
 - (c) conducting therapeutic profiling of an agent identified as an inhibitor in step (b) for efficacy and toxicity in one or more animal models; and

(d) formulating a pharmaceutical preparation including one or more agents identified in step (c) as having an acceptable therapeutic profile.

102. The method of claim 101, further including the step of establishing a system for distributing the pharmaceutical preparation for sale, and optionally including establishing a sales group for marketing the pharmaceutical preparation.

103. A method of conducting a drug discovery business comprising:

- (a) identifying, by the assay of claim 41, one or more agents which agonize CatSper2 activity;
- (b) determining if an agent identified in step (a), or an analog thereof, increases at least one of sperm motility or egg penetrance;
- (c) conducting therapeutic profiling of an agent identified as an agonist in step (b) for efficacy and toxicity in one or more animal models; and
- (d) formulating a pharmaceutical preparation including one or more agents identified in step (c) as having an acceptable therapeutic profile;

104. The method of claim 101, further including the step of establishing a system for distributing the pharmaceutical preparation for sale, and optionally including establishing a sales group for marketing the pharmaceutical preparation.

105. The method of claim 103, wherein step (a) comprises identifying one or more agents which agonize the activity of wild type CatSper2.

106. The method of claim 103, wherein step (a) comprises identifying one or more agents which agonize the activity of a CatSper2 protein containing one or more mutations.

107. A method of conducting a reproductive medicine business comprising:

- (a) examining a sperm sample from a male patient, wherein said patient is experiencing a fertility problem;
- (b) determining if said sperm are characterized by at least one of a decrease in motility or a decrease in egg penetrance;

- (c) performing *in vitro* analysis to determine the efficacy of a CatSper2 agonist in increasing at least one of sperm motility or egg penetrance;
- (d) establishing a treatment regimen comprising administering an amount of a CatSper2 agonist effective to increase at least one of sperm motility or egg penetrance in said male.

108. The method of claim 107, further including a step wherein said male is monitored by a physician to evaluate improvement in fertility.

109. The method of claim 107, further including a step of billing the patient or the patient's health care provider.

110. A method of conducting a contraceptive medicine business comprising:

- (a) providing a pharmaceutical preparation discovered by an assay of claim 41, wherein said preparation inhibits the activity of CatSper2;
- (b) providing instructions to physicians and health care providers for the administration of an amount of said pharmaceutical preparation effective to inhibit the activity of CatSper2, wherein said effective amount is sufficient to prevent pregnancy.

111. The method of claim 110, further including the step of establishing a system for distributing the pharmaceutical preparation for sale, and optionally including establishing a sales group for marketing the pharmaceutical preparation.